ABSTRACT BACKGROUND New cholesterol guidelines emphasize 10-year risk of cardiovascular disease (CVD) to identify adults
These latest guidelines increase the number of adults in the United States recommended for statin therapy by nearly 13 million (1, 2) . The majority of the increase is among adults 60 years of age or older, in whom statin therapy is now recommended for 80% or more of patients (3) . These newer guidelines base their primary prevention treatment recommendations on the 10-year predicted CVD risk model using the Pooled Cohort Equations.
The thresholds for therapeutic consideration were Ideally, one would want to treat a majority of those patients who will subsequently develop a CVD event (high sensitivity) while avoiding unnecessary treatment among those patients not who will not develop a CVD event (high specificity). Yet to date, it is unclear whether the guideline-recommended thresholds achieve this goal among certain subgroups, such as younger and older adults, and women and men.
Furthermore, it is possible that the performance of the guidelines could be improved if treatment thresholds were age and sex specific.
Using data on adults from the Framingham Offspring Study, we estimated the sensitivity and specificity of current ACC/AHA cholesterol treatment guidelines for identifying adults at risk for CVD. We also estimated the impact of varying the 10-year risk thresholds that are used to identify adults for statin therapy across age and sex groupings, to determine how sensitivity and specificity may be affected by using different risk thresholds.
METHODS
Our study population included adults from the Fra- Board. All analyses were performed using SAS software version 9.3 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Our study population included 3,685 adults; their average age was 57.2 years. Table 1 shows the characteristics of the study population at the In younger women and younger men (40 to 55 years of age), the guideline sensitivity for identifying adults who would develop CVD over the next 10 years by using a cutoff of 7.5% was relatively low, with only 36% of future cases identified as treatment candidates in women and 49% of future cases identified in men. Reducing the 10-year risk threshold to 5% in women and men who were 40 to 55 years of age markedly improved sensitivity (from 36% to 48% in women and from 48% to 71% in men), with only a modest reduction in specificity (90% to 87% in women and 72% to 56% in men).
More marked differences were seen in guideline performance between men and women who were 56 to 65 years of age. Because 84% of men were recommended for statins in this age group at a cutoff of 7.5% versus only 29% of women, sensitivity was markedly higher in men compared with women (90% vs. 49%, respectively). Using a risk threshold of 7.5%, the guidelines were able to identify 9 in 10 men who would develop CVD over the next 10 years, but fewer than 1 in 2 women. When the optional cutoff of 5% for statin use was extended to women 56 to 65 years of age, sensitivity improved to 65%.
In men 66 to 75 years of age, guideline sensitivity and specificity varied little across treatment thresholds because nearly all men in this age group were recommended for statin therapy-even at a risk threshold of 10% (97% recommended). Consequently, specificity for a threshold of 10% or less was extremely low (3%). Raising the 10-year risk cutoff in older men to 15% led to a reduction in the number of men recommended for statin therapy (97% to 89%), with no change in sensitivity (96% to 96%) but improved specificity (3% to 14%). Even when the threshold was increased to 20% (thereby reducing the number treated with a statin to 68%), sensitivity was reduced only to 87%, whereas specificity improved to 40%. Similarly, among older women, increasing the threshold from 7.5% to 10% reduced the sensitivity only slightly from 95% to 87%, but it nearly doubled the specificity from 17% to 34%.
DISCUSSION
The newest ACC/AHA cholesterol guidelines substantially increase the number of individuals recommended for statin therapy, particularly among older women and men and among adult men of all ages.
Our study evaluated the treatment thresholds used by the new guidelines to determine the number treated who are likely to develop actual CVD events over the next decade. We found that guideline treatment performance varied in clinically significant ways across age-and sex-specific groups. Existing thresholds had decreased sensitivity for predicting future CVD events in women and younger adults, and they had poor specificity for predicting such events in men and older adults. Most importantly, we found that guideline treatment performance could be improved by selecting age-and sex-specific thresholds for statin initiation.
Previous work has questioned the accuracy of the Pooled Cohort Equations in predicting 10-year atherosclerotic CVD risk, with criticism focusing on the calibration and discrimination of the risk estimates (6,7). However, as applied in the new AHA/ACC cholesterol guidelines, the Pooled Cohort Equations are used not to predict precise risk, but rather to stratify adults into "high-risk" ($7.5% 10-year risk) or "low-risk" categories using binary risk categories.
Therefore, the continuous precision of the Pooled Cohort Equations may actually be less important than its ability to divide patients appropriately into those above and below a particular risk threshold.
Our objective was not to examine the calibration of the Pooled Cohort Equations, but rather to focus on the practical issue of altering statin treatment thresholds by age-and sex-specific groups to determine the performance characteristics of these treatment recommendations.
Our study highlights 2 key concerns regarding the use of a fixed risk threshold in any type of treatment guideline. First, the 7.5% threshold adopted by the current cholesterol guidelines may not be optimal for identifying younger adults in need of statin therapy.
Using the "optional" 5% threshold, we observed an The new blood cholesterol guidelines from the American College of Cardiology/American Heart Association base statin therapy recommendations on a 10-year fixed risk threshold of 7.5% for atherosclerotic cardiovascular disease (ASCVD). Varying the 10-year risk thresholds in women (top) and men (bottom) of specific age groups correspondingly alters the performance of the recommendations in regard to sensitivity and specificity.
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Risk Thresholds for Statins biomarkers, and algorithms focused on 30-year or lifetime risk should be examined for their impact on the sensitivity of future CVD detection, particularly in these risk groups.
Our second major concern is that although most older adults (66 to 75 years of age) were recommended for statin therapy, that recommendation was made significantly more for men than for women in this age group. Because most (9 in 10) of the older men had a 10-year risk of 7.5%, the specificity of this recommendation was poor among older men, thus leading to high rates of potentially unnecessary statin treatment. We found that guideline specificity in older men can be substantially improved with no impact on sensitivity by raising the treatment threshold to 15%. Nonetheless, the high proportion of those patients recommended for treatment and the low specificity achieved in this age group suggest that efforts should be dedicated to improving discrimination between those who require statin treatment and those who do not.
We found that a slight adjustment of classification thresholds can improve the overall operating characteristics of the current fixed 7.5% threshold guideline. For example, when we used a lower threshold of 5% in adults 40 to 55 years of age, a 7.5% threshold in those 56 to 65 years of age, a 10% threshold in women 66 to 75 years of age, and a 15% threshold in men 66 to 75 years of age, the overall number of adults recommended for treatment increased by only 2% (from 47% to 49%), whereas the overall guideline sensitivity increased from 71% to 77%, with only a small decrease in specificity (from 58% to 56%).
We acknowledge that there is no such thing as a perfect threshold; improved sensitivity for predicting future events comes with the tradeoff of reduced specificity and vice versa. As a result, providers and patients must weigh potential risks of statin therapy (including cost considerations) against the perceived benefit of these drugs when deciding whether or not to use statin therapy for primary prevention. As the guidelines suggest, the thresholds proposed should be used as starting points in a conversation between patients and providers, with a focus on shared decision making; however, our study demonstrates that these treatment thresholds should not be fixed at an arbitrary number, but rather determined with consideration of a patient's age and sex. 
